risk of infection and mitigation strategies in patients with myeloma treated with bispecifics
Published 1 year ago • 57 plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
1:22
risk of infection in patients with multiple myeloma treated with bispecific antibodies
-
0:43
the importance of improving precision when risk stratifying patients with multiple myeloma
-
1:22
using molecular techniques to define risk in patients with myeloma
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
9:22
myeloma:interpreting test results | bmj learning
-
5:59
what is hrmm (high-risk multiple myeloma)?
-
5:19
a 17-year fight against multiple myeloma
-
6:09
bispecific antibodies | high impact topic (hit)
-
2:07
special approaches to myeloma patients with high-risk cytogenetics
-
0:57
risk stratification in multiple myeloma
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
2:45
an insight into clinical risk factors for progression in mpns
-
1:29
insights into the biology of high-risk myeloma and advances being made in this space
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
2:36
high-risk disease biology in multiple myeloma
-
2:42
enhancing outcomes in multiple myeloma with immune-based strategies
-
2:00
defining and treating high-risk multiple myeloma
-
1:36
identification of high-risk disease using molecular profiling by mymap
-
8:13
treatment strategies for high-risk mm
-
0:52
novel strategies to evaluate biomarkers of interest in multiple myeloma